Sargent Investment Group LLC Has $381,000 Stock Holdings in Stryker Co. (NYSE:SYK)

Sargent Investment Group LLC increased its holdings in shares of Stryker Co. (NYSE:SYK) by 7.1% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,055 shares of the medical technology company’s stock after acquiring an additional 70 shares during the quarter. Sargent Investment Group LLC’s holdings in Stryker were worth $381,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in SYK. Czech National Bank lifted its position in shares of Stryker by 8.1% in the 3rd quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock worth $25,231,000 after purchasing an additional 5,235 shares during the period. Dynamic Advisor Solutions LLC lifted its position in shares of Stryker by 2.3% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 2,990 shares of the medical technology company’s stock worth $1,080,000 after purchasing an additional 67 shares during the period. Atomi Financial Group Inc. lifted its position in shares of Stryker by 2.3% in the 3rd quarter. Atomi Financial Group Inc. now owns 2,091 shares of the medical technology company’s stock worth $755,000 after purchasing an additional 47 shares during the period. Sugarloaf Wealth Management LLC lifted its position in shares of Stryker by 32.7% in the 3rd quarter. Sugarloaf Wealth Management LLC now owns 446 shares of the medical technology company’s stock worth $161,000 after purchasing an additional 110 shares during the period. Finally, Reliant Investment Management LLC lifted its position in shares of Stryker by 0.9% in the 3rd quarter. Reliant Investment Management LLC now owns 15,200 shares of the medical technology company’s stock worth $5,491,000 after purchasing an additional 138 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE SYK opened at $399.01 on Thursday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market cap of $152.11 billion, a price-to-earnings ratio of 51.42, a PEG ratio of 2.78 and a beta of 0.96. The company has a fifty day moving average price of $376.87 and a 200-day moving average price of $364.00.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the business posted $3.46 earnings per share. As a group, equities research analysts predict that Stryker Co. will post 13.5 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.84%. Stryker’s payout ratio is 43.30%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SYK. Truist Financial boosted their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Evercore ISI boosted their target price on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Piper Sandler reiterated an “overweight” rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group boosted their target price on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $419.37.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.50% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.